JosephA.LudwigIVMD

Asst. Professor, MD Anderson Cancer Center

Dr. Ludwig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Asst. Professor at MD Anderson Cancer Center, Dept. of Sarcoma Medical Oncology. Primary research focus on Ewing sarcoma and DSRCT.

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1998

PubMed

Primary Intrathoracic Synovial Sarcoma: An Analysis of Outcomes of This Rare Disease.
Riddhi R Patel, Andrew J Bishop, Alexander J Lazar, Patrick P Lin, Robert S Benjamin
Cancers. 2025-02-22
Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?
Riddhi R Patel, George L Delclos, Stacia M DeSantis, Michael B Cannell, Philip J Lupo
American Journal of Clinical Oncology. 2025-01-01
2 citations
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
Paul A Meyers, Noah Federman, Najat Daw, Peter M Anderson, Lara E Davis
Journal of Clinical Oncology. 2024-11-01

Journal Articles

Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Alexander J Lazar, Joseph A Ludwig, Cynthia E Herzog, Raphael E Pollock, Clinical Cancer Research
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma
Joseph Ludwig IV, MD, Clinical Cancer Research

$Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting$
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual MeetingNovember 11th, 2020
$Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020$
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020September 21st, 2020
MD Anderson Researchers Receive Over $25.5 Million in CPRIT FundingFebruary 23rd, 2024
Join now to see all